Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.

Recruiting now · Phase 4

Conditions studied: Infertility, Obesity

In brief

This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.

Key facts

Study ID

NCT07242534

Run by

Fundacion Dexeus

People needed

62

Starts

2026-01-19

Expected to finish

2027-05-01

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older, up to 38. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• ≤ 38 years
• AMH >= 1 ng/mL or AFC >= 6
• Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
• Scheduled for IVF with freeze-all strategy

You may not qualify if…

• Severe male factor (sperm concentration <5M/mL)
• Type 2 diabetes mellitus
• Prior use of GLP-1 Ras within the past year
• Uncontrolled thyroid disorders
• Contraindications to IVF or semaglutide treatment
• Patients with chronic inflammatory diseases
• Family history of hereditary or chromosomal diseases
• Use of glucocorticoids or immunosuppressants
• PGT-A
• Use of medications affecting metabolism or inflammation

Where it is running

• Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus — Barcelona, Spain (enrolling)
• Dexeus Mujer Sabadell — Sabadell, Barcelona, Spain
• Dexeus Mujer Sant Cugat — Sant Cugat del Vallès, Barcelona, Spain
• Dexeus Mujer Reus — Reus, Tarragona, Spain
• Dexeus Mujer Tarragona — Tarragona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.